Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection.

Case Reports in Hepatology Pub Date : 2024-01-11 eCollection Date: 2024-01-01 DOI:10.1155/2024/5556907
B-O Stüben, D P Hoyer, S Radunz, F Saner, H Schmidt, H A Baba, J W Treckmann, L I Mazilescu
{"title":"Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection.","authors":"B-O Stüben, D P Hoyer, S Radunz, F Saner, H Schmidt, H A Baba, J W Treckmann, L I Mazilescu","doi":"10.1155/2024/5556907","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute liver injury is a life-threatening condition with disparate aetiology. Swift and adequate interdisciplinary treatment is essential to assure the best possible outcomes in these patients. Investigations to identify the cause of the condition and the implementation of quick and appropriate treatment can be lifesaving. <i>Case Presentation</i>. In October 2022, an otherwise healthy 66-year-old male presented at the University Hospital Essen with acute liver injury following an inclisiran injection for hypercholesterinaemia. Four weeks following admission, the patient fully recovered after initially receiving short-term cortisol therapy and open albumin (OPAL) dialysis, and the indices of liver, kidney, and coagulation function were normal at discharge.</p><p><strong>Conclusion: </strong>This is to our knowledge the first reported acute liver injury due to an inclisiran injection. Cortisol in combination with OPAL dialysis is an effective method for the treatment of acute liver injury caused by inclisiran injury, and in this case, it led to a near-complete reversal of the acute liver injury at the time of discharge.</p>","PeriodicalId":30295,"journal":{"name":"Case Reports in Hepatology","volume":"2024 ","pages":"5556907"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796182/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/5556907","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Acute liver injury is a life-threatening condition with disparate aetiology. Swift and adequate interdisciplinary treatment is essential to assure the best possible outcomes in these patients. Investigations to identify the cause of the condition and the implementation of quick and appropriate treatment can be lifesaving. Case Presentation. In October 2022, an otherwise healthy 66-year-old male presented at the University Hospital Essen with acute liver injury following an inclisiran injection for hypercholesterinaemia. Four weeks following admission, the patient fully recovered after initially receiving short-term cortisol therapy and open albumin (OPAL) dialysis, and the indices of liver, kidney, and coagulation function were normal at discharge.

Conclusion: This is to our knowledge the first reported acute liver injury due to an inclisiran injection. Cortisol in combination with OPAL dialysis is an effective method for the treatment of acute liver injury caused by inclisiran injury, and in this case, it led to a near-complete reversal of the acute liver injury at the time of discharge.

一名健康患者注射 PCSK9 抑制剂后出现的药物性肝损伤
背景:急性肝损伤是一种危及生命的疾病,其病因各不相同。迅速、充分的跨学科治疗对于确保这些患者获得最佳治疗效果至关重要。通过调查查明病因并实施快速、适当的治疗可以挽救患者的生命。病例介绍。2022 年 10 月,埃森大学医院收治了一名因高血脂症注射伊曲西兰后出现急性肝损伤的 66 岁健康男性患者。入院四周后,患者在接受短期皮质醇治疗和开放性白蛋白(OPAL)透析后完全康复,出院时肝、肾和凝血功能指标正常:据我们所知,这是首次报道因注射替吉兰而导致的急性肝损伤。结论:据我们所知,这是第一例因注射替吉奥而导致急性肝损伤的报道。皮质醇联合 OPAL 透析是治疗因替吉奥而导致的急性肝损伤的有效方法,在该病例中,皮质醇联合 OPAL 透析使急性肝损伤在出院时几乎完全逆转。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
12
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信